News Pfizer’s migraine push builds with Zavzpret nod Zavzpret is first CGRP to be approved in a nasal formulation designed to be rapid acting.
News Neumora laid low by depression trial failure The first of three phase 3 trials of Neumora's novel antidepressant navacaprant has ended in failure, wreaking havoc with its share price.
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.
